Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming virtual investor conferences: Share this article. Find real-time KOD - Kodiak Sciences Inc stock quotes, company profile, news and forecasts from CNN Business. Kodiak Sciences Inc. Nov 16, 2020, 16:01 ET. Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS. 11/09: KODIAK SCIENCES… Kodiak Sciences Inc. Nov 20, 2020, 16:03 ET. 11/17: KODIAK SCIENCES: Announces Pricing of $560.9 Million Public Offering of Common .. PR. March 7, 2019 Kodiak Sciences to Present at the Barclays Global Healthcare Conference. Most relevant news about KODIAK SCIENCES INC. 07/28: KODIAK SCIENCES: Lonza's Ibex Dedicate to Support the Commercial Manufacture of.. AQ. Kodiak Sciences INC. 2631 Hanover Street Palo Alto, CA 94304 United States of America. Share this article. News provided by. February 8, 2019 Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a … News for Kodiak Sciences Inc Registered Shs. Feb 10, 2020. Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2020. PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. … Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Press Releases; Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights. A high-level overview of Kodiak Sciences Inc. (KOD) stock. 11/16: KODIAK SCIENCES: Announces Proposed Offering of Common Stock: PR. Additional Formats PDF Version. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country. 125.04 0.34 (0.27%) Upgrade to Real-Time Regular Market . PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. … 05/11 : KODIAK SCIENCES: to Present at the Bank of America Merrill Lynch Health Care Co.. PR. KOD | Complete Kodiak Sciences Inc. stock news by MarketWatch. Share this article. PALO ALTO, Calif., Nov. 9, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing … 11/12 : KODIAK SCIENCES: to Present at Upcoming Conferences: PR. Billionaires Are Gobbling Up These 3 Healthcare Stocks. News provided by. Get the latest Kodiak Sciences Inc (KOD) stock news and headlines to help you in your trading and investing decisions. … View today's stock price, news and analysis for Kodiak Sciences Inc. (KOD). Company profile page for Kodiak Sciences Inc including stock price, company news, press releases, executives, board members, and contact information 07/16: KODIAK SCIENCES: to Host R&D Webcast to Review Recent Data from the Ongoing Pha.. PR. Zacks 15h News provided by. View real-time stock prices and stock quotes for a full financial overview. 05/28: KODIAK SCIENCES: to Present at Upcoming Conferences: PR. Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus. Kodiak Sciences Inc. (KOD) Q1 2020 Earnings Call Transcript. Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcoming virtual investor conferences: Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Kodiak Sciences Inc. … Kodiak Sciences Inc. (KOD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). View the latest Kodiak Sciences Inc. (KOD) stock price, news, historical charts, analyst ratings and financial information from WSJ. KODIAK SCIENCES INC. : News, information and stories for KODIAK SCIENCES INC. | Nasdaq: KOD | Nasdaq LPL Financial LLC Raises Stock Position in Lear Co. (NYSE:LEA) » NEXT . Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. News Releases March 28, 2019 Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights. PALO ALTO, Calif., Feb. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. , a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal... | November 14, 2020 Kodiak Sciences Inc. Nov 16, 2020, 06:53 ET. November 9, 2020 at 5:30 AM EST. PALO ALTO, Calif., Nov. 9, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a … Additional Formats PDF Version. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country. All news about KODIAK SCIENCES INC. 04:21p: KODIAK SCIENCES INC.: Other Events, Financial Statements and Exhibits (form 8-K.. AQ. Kodiak Sciences Announces Pricing of $560.9 Million Common Stock Offering. Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Share this article. Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. PDF Version. Kodiak Sciences News . Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country. News provided by. Follow KOD. Kodiak Sciences INC. 1200 Page Mill Road Palo Alto, CA 94304 United States of America. Kodiak Sciences INC. 1200 Page Mill Road Palo Alto, CA 94304 United States of America. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. > News - Sub Nav. Kodiak Sciences Inc. Nov 09, 2020, 05:30 ET. Apr 11, 2020.